|
|
|
| Research progress of inositol and insulin resistance in patients with polycystic ovary syndrome |
| LI Yangyang1 HOU Lihui2▲ LI Yan2 SUN Miao2 HAO Songli2 XIA Xiaoyan3 |
1.Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China;
2.Department of Gynaecology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China; 3.Department of Traditional Chinese Medicine, Hainan Women and Children’s Medical Center, Hainan Province, Haikou 570206, China |
|
|
|
Abstract Polycystic ovary syndrome (PCOS) is one of the most common reproductive endocrine disorders in women. Typical clinical manifestations include oligo-ovulation and/or anovulation, excess androgens, and polycystic ovaries. PCOS is associated with an increased risk of diabetes mellitus type 2 and cardiovascular disease, and its main pathological mechanism is insulin resistance (IR). IR is a pathological association between PCOS metabolism and reproductive abnormalities. In the past decade, inositol has been increasingly used in the treatment of PCOS due to its natural, non-toxic, and effective properties. Compared with Metformin, insulin sensitizers containing inositol are recommended for the treatment of patients with PCOS. This review intends to discuss it from the point of view of inositol in the treatment of PCOS-IR.
|
|
|
|
|
|
[1] Zeng X，Xie YJ，Liu YT，et al. Polycystic ovarian syndrome：correlation between hyperandrogenism，insulin resistance and obesity [J]. Clin Chim Acta，2020，502：214-221.
[2] 陈思琦，李佳欣，吴鑫宇，等.胰岛素抵抗分子机制研究进展[J].辽宁中医药大学学报，2020，22（2）：87-92.
[3] Kataoka J，Tassone EC，Misso M，et al. Weight management interventions in women with and without PCOS：a systematic review [J]. Nutrients，2017，9（9）：996.
[4] Facchinetti F，Orru B，Grandi G，et al. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome （PCOS）：a meta-analysis of randomized clinical trials [J]. Gynecol Endocrinol，2019，35（3）：198-206.
[5] Stracquadanio M，Ciotta L，Palumbo MA. Effects of myo-inositol，gymnemic acid，and L-methylfolate in polycystic ovary syndrome patients [J]. Gynecol Endocrinol，2018，34（6）：495-501.
[6] Bastian W. Genes with linkage or association with type 2 diabetes mellitus [J]. J Pediatr Endocrinol Metab，2002，15 Suppl 1：471-484.
[7] 孙加琳，荆凡波，徐文，等.胰岛素受体底物的功能及其基因多态性与2型糖尿病的关系[J].中国药房，2018，29（3）：369-374.
[8] Patti ME，Kahn BB. Nutrient sensor links obesity with diabetes risk [J]. Nat Med，2004，10（10）：1049-1050.
[9] Shah OJ，Wang Z，Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion，insulin resistance，and cell survival deficiencies [J]. Curr Biol，2004，14（18）：1650-1656.
[10] He T，Liu Y，Zhao S，et al. Comprehensive assessment the expression of core elements related to IGFIR/PI3K pathway in granulosa cells of women with polycystic ovary syndrome [J]. Eur J Obstet Gynecol Reprod Biol，2019， 233：134-140.
[11] Ueki K，Fruman DA，Brachmann SM，et al. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival [J]. Mol Cell Biol，2002，22（3）：965-977.
[12] Michell RH. Do inositol supplements enhance phospha-tidylinositol supply and thus support endoplasmic reticulum function？[J]. Br J Nutr，2018：1-6.
[13] Sortino MA，Salomone S，Carruba MO，et al. Polycystic ovary syndrome：insights into the therapeutic approach with inositols [J]. Front Pharmacol，2017，8：341.
[14] Bizzarri M，Fuso A，Dinicola S，et al. Pharmacodynamics and pharmacokinetics of inositol（s）in health and disease [J]. Expert Opin Drug Metab Toxicol，2016，12（10）：1181-1196.
[15] Laganà AS，Garzon S，Casarin J，et al. Inositol in polycystic ovary syndrome：restoring fertility through a pathophysiology-based approach [J]. Trends Endocrinol Metab，2018，29（11）：768-780.
[16] Caputo M，Bona E，Leone I，et al. Inositols and metabolic disorders：From farm to bedside [J]. J Tradit Complement Med，2020，10（3）：252-259.
[17] Jamka M，Kulczyński B，Juru■ A，et al. The Effect of the Paleolithic Diet vs. Healthy Diets on Glucose and Insulin Homeostasis：A Systematic Review and Meta-Analysis of Randomized Controlled Trials [J]. J Clin Med，2020，9（2）：296.
[18] 杜静，吴日然，林秀峰，等.肌肉肌醇联合D手性肌醇治疗胰岛素抵抗多囊卵巢综合征患者的临床效果[J].中国医药，2018，13（9）：1389-1393.
[19] 周芳.Myo-肌醇对多囊卵巢综合征患者脂代谢异常及胰岛素抵抗的改善作用及机制[J].山东医药，2018，58（29）：73-75.
[20] Hibberd R，Raine-Fenning N，Thornton J. Re：Inositol treatment of anovulation in women with polycystic ovary syndrome：a meta-analysis of randomised trials [J]. BJOG，2018，125（4）：509.
[21] Ravanos K，Monastra G，Pavlidou T，et al. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality [J]. Eur Rev Med Pharmacol Sci，2017，21（23）：5491-5498.
[22] Mendoza N，Galan MI，Molina C，et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI：a randomized
controlled trial [J]. Gynecol Endocrinol，2020，36（5）：398-401.
[23] Gateva A，Unfer V，Kamenov Z. The use of inositol（s）isomers in the management of polycystic ovary syndrome：a comprehensive review [J]. Gynecol Endocrinol，2018， 34（7）：545-550.
[24] Szkudelski T，Hertig I，Szkudelska K. Lack of effects of myo-inositol on metabolism of primary rat adipocytes [J]. Arch Physiol Biochem，2018，124（4）：344-350.
[25] Palomba S，Santagni S，Falbo A，et al. Complications and challenges associated with polycystic ovary syndrome：current perspectives [J]. Int J Womens Health，2015，7：745-763.
[26] 高丽鹤.肌肉肌醇、D-手性肌醇及二者合用对HepG2胰岛素抵抗细胞葡萄糖消耗量的改善作用[D].青岛：青岛大学，2016.
[27] 尹雪萍.肌肉肌醇对糖尿病大鼠糖代谢和胃肠动力的影响研究[D].青岛：青岛大学，2018.
[28] Zhang Y，Li C，Zhang W，et al. Decreased insulin resistance by myo-inositol is associated with suppressed interleukin 6/phospho-STAT3 signaling in a rat polycystic ovary syndrome model [J]. J Med Food，2020，23（4）：375-387.
[29] Cheng F，Ge X，Gao C，et al. The distribution of D-chiro-inositol in buckwheat and its antioxidative effect in HepG2 [J]. J Cereal Sci，2019，89：102808.
[30] Zhang H，Lv Y，Li Z，et al. The efficacy of myo-inositol supplementation to prevent gestational diabetes onset：a meta-analysis of randomized controlled trials [J]. J Matern Fetal Neonatal Med，2019，32（13）：2249-2255.
[31] Guo X，Guo S，Miao Z，et al. Myo-inositol lowers the risk of developing gestational diabetic mellitus in pregnancies：a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis [J]. J Diabetes Complications，2018，32（3）：342-348.
[32] Benelli E，Del Ghianda S，Di Cosmo C，et al. A combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women [J]. Int J Endocrinol，2016， 2016：3204083.
[33] Shokrpour M，Foroozanfard F，Afshar Ebrahimi F，et al. Comparison of myo-inositol and metformin on glycemic control，lipid profiles，and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome：a randomized controlled clinical trial [J]. Gynecol Endocrinol，2019，35（5）：406-411.
[34] Pourghasem S，Bazarganipour F，Taghavi SA，et al. The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole [J]. Arch Gynecol Obstet，2019，299（4）：1193-1199.
[35] Regidor PA，Schindler AE，Lesoine B，et al. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature [J]. Horm Mol Biol Clin Investig，2018，34（2）.
[36] Longo M，Alrais M，Tamayo EH，et al. Vascular and metabolic profiles in offspring born to pregnant mice with metabolic syndrome treated with inositols [J]. Am J Obstet Gynecol，2019，220（3）：279.e1-279.e9.
[37] Montanino Oliva M，Buonomo G，Calcagno M，et al. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women [J]. J Ovarian Res，2018， 11（1）：38.
[38] Raffone E，Rizzo P，Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women [J]. Gynecol Endocrinol，2010， 26（4）：275-280.
[39] Facchinetti F，Appetecchia M，Aragona C，et al. Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus：a further help for human reproduction and beyond [J]. Expert Opin Drug Metab Toxicol，2020，16（3）：255-274.
[40] Facchinetti F，Unfer V，Dewailly D，et al. Inositols in Polycystic Ovary Syndrome：An Overview on the Advances [J]. Trends Endocrinol Metab，2020，31（6）：435-447. |
|
|
|
